Aptinyx Stock Price

-0.01 (-0.39%)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aptinyx Inc APTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.39% 2.54 08:47:36
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
2.53 2.54 0.01 - -
Trades Volume Avg Volume 52 Week Range
15 1,359 415,326 2.3413 - 6.47
Last Trade Time Type Quantity Stock Price Currency
08:47:36 formt 600 $ 2.54 USD

Aptinyx Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 170.10M 66.97M 53.05M $ 1.57M $ - -1.02 -2.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 2.30%

more financials information »

Aptinyx News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical APTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.762.782.34132.56462,962-0.22-7.97%
1 Month2.913.07812.34132.75423,475-0.37-12.71%
3 Months3.954.252.34133.19403,603-1.41-35.7%
6 Months3.054.552.34133.53575,078-0.51-16.72%
1 Year3.946.472.34133.77708,033-1.40-35.53%
3 Years17.4032.251.605.20394,496-14.86-85.4%
5 Years17.4032.251.605.20394,496-14.86-85.4%

Aptinyx Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.